Month: February 2017

The Neutrino Donut, LLC – Rocking All over the World

On By Earle HagerIn Global Technology Projects, Industry TrendsLeave a comment

Global entrepreneurship is a blast. Over the last few years, we have completed projects in the USA, and globally in diverse places including India, Korea, Hungary, Chile, Ukraine, Viet Nam, Latvia, Mexico, England, Saudi Arabia, Portugal and Armenia.

We has worked in, developed and managed offset programs at the University of California, Irvine and The University of Texas at Austin.

Mr. Hager is a Fellow at the IC2 Institute at The University of Texas at Austin.

For an updated list of projects, please view my LinkedIn profile at https://www.linkedin.com/in/earlehager.

Thank you to Creedence Clearwater Revival for the inspiration.

Tech Transfer – The Missing Piece – Time

On By Earle HagerIn Industry Trends, University Technology CommercializationLeave a comment

Tech transfer offices have many challenges. Identification of technologies, allocation of patent costs, decisions on what technologies to take forward into the marketplace, and the management of the external relationships to be successful in licensing.

This last area is the most time consuming and the greatest challenge. To succeed, these organizations need to have ongoing relationships with major and minor players in various marketplaces who will provide feedback on technologies.

At The Neutrino Donut, LLC, this is what we do. We know people. Lots of them, in almost every market. We can save you time by marketing your technologies to the right people and get it done quickly. We can help you set up these relationships so the next time you want to connect with the company, you will already know who to call.

Save yourself some time. Make yourself some money. Give us a call and let us bring out network to your organization and see what we can make happen.

Neutrino Donut Project – Patient Reported Outcomes – Commercialization Assessment

On By Earle HagerIn Technology Assessments, Technology MarketingLeave a comment

The Neutrino Donut completed a commercialization assessment for a technology relating to patient reported outcomes. The use of interviews to evaluate patients is commonplace and part of the development of an overall well being program for the patient. To distinguish one technology opportunity from another, the tech must go through an FDA approval process as well as extensive testing against the historical data from a healthcare organization to ensure hard numbers and cost tracking and savings over a large population and time frame.

In developing the questionnaire, the innovators will look to understand the types of data being collected, the questions which can be asked and answers, and create a link between the two groups.

With the implementation of the Affordable Care Act, the population of patients available for statistical evaluation has greatly increased. Additionally, medical systems and insurance companies focus on cost savings across a population, which would include more effective identification of patients as well as treatment plans which are closely tracked.

Sometimes, it’s not the technology. It’s the data produced by the technology.

Business Development Project – The Neutrino Donut, LLC – Licensing / Distribution Opportunity

On By Earle HagerIn Global Technology Projects, Technology Assessments, Technology MarketingLeave a comment

The Neutrino Donut, LLC offers the following licensing opportunity in collaboration with EU entity GlobeTech Innovation. All materials presented are public and can be shared with internal and external partners. For more information, please contact Earle Hager, Managing Partner, at ehager81@gmail.com or +1 512 431 3940.

TECHNOLOGY SUMMARY

Loccnel is a novel scientifically proven technology and ready to market product – bioactive peptide based cosmetics, Loccnel Anti Age – Every Day Complex and Loccnel® Anti Age – Every Night Treatment. It has a patent application (Czech patent application PV 2015-707) and has additional paths forward for product development. The process is within the priority period for PCT filings. The products are based upon Alaptide, a novel synthesis and use of bioactive peptide to advance skin regeneration. The products are scientifically proven to provide active cell protection with significant effects on the quality of the skin and strong regenerative effect and are suitable for both women and men. The products have excellent local and systemic tolerability and non-oily texture and have no health burden – excreted in unchanged structure.

DEVELOPMENT STATUS

 Specific stability tests were successfully performed, including:

  • Physical / Chemical Stability Tests
  • Microbiological Quality Testing
  • Preservative Challenge Testing
  • Stability and Shelf Life Testing
  • Non-Animal Safety / Toxicity Testing
  • Microbiological Stability Tests
  • Packaging Stability Tests
  • Custom Testing
  • All results are in compliance with legal requirement for cosmetic products.

Preclinical studies demonstrated positive effect on the proliferation of cells, physiological and regenerative processes, such as reducing and removing wrinkles and scars, accelerating epithelization and healing process demonstrably, and stimulating growth of granulation tissue (in healing applications).

Future clinical development plans include:

  • Loccnel® 2nd generation production
  • Development of nanofiber based carrier with active healing component (plus patent protection)
  • Production of a substance optimization (patent protection)
  • Analytical assessments – for pharmaceutical-analytical documentation
  • Development of new dosage forms (patent protection)
  • Preclinical testing of the effectiveness of the SLP
  • Study of the mechanism of action – influence on epidermal growth factor
  • Metabolic studies
  • Pharmacokinetics after topical application, also penetration of a new form
  • Toxicology (genotoxicity, irritability, safety pharmacology, side effects)
  • Clinical trials – necessary from I to III.

KEY INNOVATORS

These products were developed by Dr. Pavel Martásek, an internationally renowned expert in research of structural functional determinants of the synthesis of gaseous molecules, important agents in normal and pathologic conditions, and in the field of heme synthesis and degradation and Dr. Vladimír Král, a leading researcher in supramolecular chemistry, nanotechnology, and molecular engineering.

NEXT STEPS

The company is seeking a partner for Loccnel® products – sales / distribution and licensing the technology as well as a research and development partner for next generation products. The company is looking for a partner who can provide global leadership in the distribution of the product.

For more information, please contact Earle Hager, Managing Partner, The Neutrino Donut, LLC at ehager81@gmail.com or +1 512 431 3940.

Neutrino Donut Project – Diabetes Technology

On By Earle HagerIn Technology Assessments, Technology Marketing, University Technology CommercializationLeave a comment

The Neutrino Donut just completed a project working with a company on a diabetes related technology. As part of the process, we helped define markets and their relating opportunities, worked with the negotiations with a university tech transfer group, and helped define the company structure. The market discussions centered around a specific v. global opportunity. The negotiations discussions with the tech transfer office had a focus on defining product development from the university perspective v. the commercial markets, anticipated carve outs for other negotiations, and the process of defining the value of the startup v. potential licenses with larger companies from the university’s perspective. The definition of the company structure centered around the long term v. short term/buy out process for the company and where the finish line was located for each strategy. The project was developed in conjunction with a patent law firm, who identified The Neutrino Donut, LLC as an effective consultant for their client.

University technologies, check them out.

Managing Millennials – Stay Current, My Friends

On By Earle HagerIn Industry TrendsLeave a comment

Much has been written about how to manage millennials, many of which seem to focus on complaints from the older management styles of X and Y generations. In evaluating the problem, we need to understand the change in the corporate agreement between the worker and the company that was in place for baby boomers.

The change is there is no agreement.

It is understood a company may take down a department, terminate everyone in a geographic or business unit, shift operations to a different state or country, downsize based upon short term stock market issues, or implement a merger with a coin flip of whose department gets to stay.

This is reality. For the worker, there is no long term loyalty since the company offers no long term loyalty. For the manager to threaten job loss, the problem is the same manager has the same threat delivered from their boss.

The worker is focused on their long term interests and goals. These interests are totally about self preservation and growth, keeping a skill set which is current to the marketplace and being agile enough to react to job / management / company changes that may cause a re-evaluation of employment status.

The people who succeed are the ones who understand this and respond to these changes. Long term employment, a sign of stability in the past, is a sign of stagnation without internal growth.

Large companies provide safety in a macro scale, but are even more vulnerable to career changes on a micro scale. Small companies have their own challenges, but have similar risks as large companies for job stability.

Stay current, my friends. Be active in the marketplace, network, and keep your skill sets up to date. Find new technologies to work with and take to the marketplace.

Startups and University Technologies – A Missed Opportunity for Entrepreneurs

On By Earle HagerIn Industry Trends, University Technology CommercializationLeave a comment

Startups miss one great opportunity – university technologies. There are multiple tech transfer offices wherever you are and the first step is in developing a relationship with the local group. Why try and commercialize your own idea when you can advance science from the university.

Technologies available for licensing cover all areas and you should focus on the area where you have expertise – whether it be medical devices, engineering, and so forth.

OK, this is the part where it gets interesting.

Work with the tech transfer office. Find a technology or technologies you want to work with. Do the research – is this available for commercialization or further research. Need help with this evaluation – call us. Develop your next steps, whether it is licensing with key partners or further development with SBIR grant opportunities. There are other grant opportunities with the NSF, NIH, and other organizations. Check out the patent or patent application. It is possible to move ahead on patent applications into the research or licensing marketplace.

Sign an option for a license agreement for a period of time with your company. Execute your next steps. SBIR grants are awarded to an external company with part of the funds going to the university for technology development. Part of the funds also go to funding salaries (like yours). The first grant is smaller, the second grant is very large. Successful SBIR grants lead to licensing.

Licensing opportunities are also available with industry clients.

At some point, you will need to fully fund the license agreement with the university, but you should recognize the option agreement will give you time to decide whether or not to proceed with the technology.

Want to discuss further? Give us a call.